RxDoctor Payments Data

Margaret Theodore, MD

Geriatric Medicine · Tampa, FLNPI 1891732640

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 107 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AstraZeneca at 32.0% of the total.

$2,236in general payments, 2019–2025

Across 107 payments — averaging $20.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$716
  • Johnson & Johnson$431
  • Novo Nordisk$250
  • GSK$163
  • Boehringer Ingelheim$110
  • Merck$96
  • plus $470 from 12 others

What the payments were for

  • Food & beverage$2,236100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,236 in reported general payments places this provider in the 85th percentile of 305 geriatric medicine providers in Florida.

See all geriatric medicine providers in Florida

Medicare billing

Part B allowed, 2024
$196,886
Medicare patients
167
Services billed
1,910

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$52,635
FarxigaDapagliflozin Propanediol23$24,496
MyrbetriqMirabegron11$5,871
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$5,234
Diclofenac Sodium17$1,575
Rimantadine Hcl41$1,491
Levothyroxine Sodium118$1,210
Ventolin HfaAlbuterol Sulfate17$1,183
Gabapentin56$1,179
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen39$890
Atorvastatin Calcium95$890
Metoprolol Succinate70$858
Alprazolam65$829
Losartan Potassium66$761
Omeprazole49$757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$53$52,63549 claims
AstraZenecaFarxiga$716$24,49623 claims
AbbVieSynthroid$42$67314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 305 geriatric medicine providers in Florida.

Other geriatric medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →